Key result
PSMB10 knockout attenuated Angiotensin II-induced atrial fibrillation, fibrosis, and inflammation in mice, suggesting PSMB10 as a potential therapeutic target for hypertensive AF.
Why the study?
Does PSMB10 knockout or inhibition reduce Angiotensin II-induced atrial fibrillation and inflammation in mice?
Does PSMB10 knockout or inhibition reduce Angiotensin II-induced atrial fibrillation and inflammation in mice?
The immunoproteasome subunit PSMB10 promotes Angiotensin II-induced atrial fibrillation and fibrosis, suggesting its inhibition could be a therapeutic target for hypertensive AF.
No takes yet. Share an insight, caveat, or question.
PSMB10 inhibition merits preclinical follow-up in hypertensive AF; leaves open any clinical role pending human data.
Li et al. (2018) studied Atrial fibrillation. PSMB10 knockout vs. Wild-type mice was evaluated on Atrial fibrillation, fibrosis, and inflammation. PSMB10 knockout attenuated Angiotensin II-induced atrial fibrillation, fibrosis, and inflammation in mice, suggesting PSMB10 as a potential therapeutic target for hypertensive AF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: